{"id":"carboplatin-periocular-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Local inflammation/conjunctivitis"},{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Systemic myelosuppression (if significant absorption)"},{"rate":null,"effect":"Cataract formation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription in cancer cells. The periocular injection route delivers the drug directly to ocular tissues, allowing high local concentrations while minimizing systemic exposure. This is particularly useful for treating intraocular malignancies where systemic chemotherapy penetration is limited.","oneSentence":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:18.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Retinoblastoma (intraocular malignancy)"},{"name":"Other intraocular tumors amenable to periocular chemotherapy"}]},"trialDetails":[{"nctId":"NCT00186888","phase":"PHASE3","title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04-07","conditions":"Retinoblastoma, Retinal Neoplasm","enrollment":107},{"nctId":"NCT02319486","phase":"PHASE4","title":"CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2009-01","conditions":"Retinoblastoma","enrollment":26},{"nctId":"NCT02137928","phase":"PHASE3","title":"Carboplatin Periocular Injection for Retinoblastoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2006-01","conditions":"Retinoblastoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["carboplatin","vincristine, carboplatin, etoposide"],"phase":"marketed","status":"active","brandName":"carboplatin periocular injection","genericName":"carboplatin periocular injection","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Retinoblastoma (intraocular malignancy), Other intraocular tumors amenable to periocular chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}